Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* PDY6045 or PDY6046 participant who:~  * completed the week 24 visit of either study PDY6045 or PDY6046,~ * was still meeting eligibility criteria for receiving treatment,~ * had agreed to continue stable dose of Interferon-β \[IFN-β\] or Glatiramer Acetate \[GA\] and consented to continue on treatment.~Exclusion Criteria:~* Any known condition or circumstance that would have prevented in the investigator's opinion, compliance or completion of the study~The above information is not intended to contain all considerations relevant to patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + IFN-β (Type: PLACEBO_COMPARATOR): Placebo (for teriflunomide) once daily concomitantly with interferon-β \[IFN-β\] for 24 additional weeks
- Teriflunomide 7 mg + IFN-β (Type: EXPERIMENTAL): Teriflunomide 7 mg once daily concomitantly with interferon-β \[IFN-β\] for 24 additional weeks
- Teriflunomide 14 mg + IFN-β (Type: EXPERIMENTAL): Teriflunomide 14 mg once daily concomitantly with interferon-β \[IFN-β\] for 24 additional weeks
- Placebo + GA (Type: PLACEBO_COMPARATOR): Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate \[GA\] for 24 additional weeks
- Teriflunomide 7 mg + GA (Type: EXPERIMENTAL): Teriflunomide 7 mg once daily concomitantly with glatiramer acetate \[GA\] for 24 additional weeks
- Teriflunomide 14 mg + GA (Type: EXPERIMENTAL): Teriflunomide 14 mg once daily concomitantly with glatiramer acetate \[GA\] for 24 additional weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).